Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 1 Study to Evaluate EMP22 PD and EMP16 PK Versus Xenical® in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2023
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Study Exploring the Supportive Effect of Acarbose in Weight Management
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2023
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase I/ Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 21, 2020
Lead Product(s) : Orlistat
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase I/ Phase II
Sponsor : CTC Clinical Trial Consultants
Deal Size : Inapplicable
Deal Type : Inapplicable